Drug lookup | Fillwise

MIDAZOLAM

All injection strengths: Limited Use (codes 495, 496)

Other products in the same Health Canada class (N05C, N05CD) — coverage varies; not interchangeable

Flurazepam (Dalmane): general benefit, Not a benefit
Nitrazepam (Mogadon): general benefit
Temazepam (Restoril): general benefit
Triazolam (Halcion): general benefit, Not a benefit
Eszopiclone (Lunesta): not a benefit
Zolpidem (Sublinox): not a benefit

1 more in the class list below

Midazolam Injection · DIN 02240286 · 5mg/mL · injection solution (with Preservative)

Limited Use — Reason for Use code 495, 496 requiredMarketed · checked 2026-09-19

StatusLimited Use — Reason for Use code 495, 496 required

Write on scriptLU code 495, 496 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 495, 496

Reason for Use code 495 For intermittent injection used for symptomatic relief in patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes. Reason for Use code 496 For continuous infusion in patients receiving palliative sedation*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.

1 brand, same coverage

Midazolam Injection · DIN 02240286 Manufacturer: Sandoz Canada Inc.; listing date 2017-05-31 Health Canada: Marketed since 2005-10-06 · brand MIDAZOLAM INJECTION · ATC N05CD08 MIDAZOLAM · form Solution · route Intramuscular, Intravenous · ingredients MIDAZOLAM 5 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Midazolam Injection: Formulary list price $4.1000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.1000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63824 · Verify on the e-Formulary ↗ (DIN 02240286)

Source record

DIN 02240286: Midazolam Injection Raw flags: sec12=Y, sec3=Y Item: 282400180; group id 525; item number 1421; lccId 00284; manufacturer id SDZ Source form: Inj Sol (with Preservative); strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.1000; ministry $4.1000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240286 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63824

Interchangeable products

Midazolam Injection · DIN 02242905 · $4.1000 Versed · DIN 00766011 · not recorded

Shortage status: not checked (no credentials)

Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS MIDAZOLAM INJECTION (midazolam) is indicated as: • an intramuscular premedication prior to surgical or diagnostic procedures. • an intravenous agent for patients requiring sedation/anxiolysis/amnesia prior to and during short endoscopic or short diagnostic procedures and direct-current cardioversion. • an alternative intravenous agent for the induction of anesthesia. • a continuous intravenous infusion in intubated, mechanically ventilated patients requiring sedation in the Intensive Care Unit (ICU). 1.1 Pediatrics Pediatrics (<18 years old): Health Canada has authorized an indication for pediatric use of MIDAZOLAM INJECTION for: • sedation, anxiolysis, and/or amnesia for diagnostic or therapeutic procedures • preanesthesia • a component of anesthesia during surgical procedures, or during treatment in critical care settings. (see 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment; 7.1.3 Pediatrics) 1.2 Geriatrics Geriatrics (>55 years old): Evidence suggests that use in the geriatric population is associated with differences in safety or effectiveness. Intravenous sedation with MIDAZOLAM IN… https://pdf.hres.ca/dpd_pm/00083597.PDF PM date: July 21, 1999 Source product: MIDAZOLAM INJECTION; DIN 02240286; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.